Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Anxiolytic Candidate in Generalized Anxiety Disorder

A new-protocol amendment and an annual report are different submissions with different purposes, clocks, and content, and treating one as a substitute for the other is a common source of regulatory error. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral anxiolytic candidate in a blinded, placebo-controlled Phase 2 dose-ranging study (96 of 240 planned adults entered). It reconciles enrollment, tabulates participants by age, sex, and race, reports blinded pooled safety data, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, drafts Form FDA 1571 entries and a cover letter, and builds a timeline to a December 31, 2027 deadline. It also explains why Canadian clinical trial filings run on separate tracks, and why an unknown count must never be reported as zero.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24419701
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Anxiolytic Candidate in Generalized Anxiety Disorder

Dorcas Koomson, Peivand Pirouzi, Gloria Anthonia Amoateng Agyemang
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Anxiolytic Candidate in Generalized Anxiety Disorder

Dorcas Koomson, Peivand Pirouzi, Gloria Anthonia Amoateng Agyemang
article en

Abstract

A new-protocol amendment and an annual report are different submissions with different purposes, clocks, and content, and treating one as a substitute for the other is a common source of regulatory error. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral anxiolytic candidate in a blinded, placebo-controlled Phase 2 dose-ranging study (96 of 240 planned adults entered). It reconciles enrollment, tabulates participants by age, sex, and race, reports blinded pooled safety data, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, drafts Form FDA 1571 entries and a cover letter, and builds a timeline to a December 31, 2027 deadline. It also explains why Canadian clinical trial filings run on separate tracks, and why an unknown count must never be reported as zero.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Anxiolytic Candidate in Generalized Anxiety Disorder — Dorcas Koomson, Peivand Pirouzi, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS